Reviews6 October 2015
A Systematic Review and Meta-analysis
    Author, Article, and Disclosure Information

    Abstract

    Background:

    Community-acquired pneumonia (CAP) is common and often severe.

    Purpose:

    To examine the effect of adjunctive corticosteroid therapy on mortality, morbidity, and duration of hospitalization in patients with CAP.

    Data Sources:

    MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through 24 May 2015.

    Study Selection:

    Randomized trials of systemic corticosteroids in hospitalized adults with CAP.

    Data Extraction:

    Two reviewers independently extracted study data and assessed risk of bias. Quality of evidence was assessed with the Grading of Recommendations Assessment, Development, and Evaluation system by consensus among the authors.

    Data Synthesis:

    The median age was typically in the 60s, and approximately 60% of patients were male. Adjunctive corticosteroids were associated with possible reductions in all-cause mortality (12 trials; 1974 patients; risk ratio [RR], 0.67 [95% CI, 0.45 to 1.01]; risk difference [RD], 2.8%; moderate certainty), need for mechanical ventilation (5 trials; 1060 patients; RR, 0.45 [CI, 0.26 to 0.79]; RD, 5.0%; moderate certainty), and the acute respiratory distress syndrome (4 trials; 945 patients; RR, 0.24 [CI, 0.10 to 0.56]; RD, 6.2%; moderate certainty). They also decreased time to clinical stability (5 trials; 1180 patients; mean difference, −1.22 days [CI, −2.08 to −0.35 days]; high certainty) and duration of hospitalization (6 trials; 1499 patients; mean difference, −1.00 day [CI, −1.79 to −0.21 days]; high certainty). Adjunctive corticosteroids increased frequency of hyperglycemia requiring treatment (6 trials; 1534 patients; RR, 1.49 [CI, 1.01 to 2.19]; RD, 3.5%; high certainty) but did not increase frequency of gastrointestinal hemorrhage.

    Limitations:

    There were few events and trials for many outcomes. Trials often excluded patients at high risk for adverse events.

    Conclusion:

    For hospitalized adults with CAP, systemic corticosteroid therapy may reduce mortality by approximately 3%, need for mechanical ventilation by approximately 5%, and hospital stay by approximately 1 day.

    Primary Funding Source:

    None.

    References

    • 1. GBD 2013 Mortality and Causes of Death CollaboratorsGlobal, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet2015;385:117-71. [PMID: 25530442] doi:10.1016/S0140-6736(14)61682-2 CrossrefMedlineGoogle Scholar
    • 2. Estenssoro EDubin ALaffaire ECanales HSáenz GMoseinco Met alIncidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med2002;30:2450-6. [PMID: 12441753] CrossrefMedlineGoogle Scholar
    • 3. Thomas CPRyan MChapman JDStason WBTompkins CPSuaya JAet alIncidence and cost of pneumonia in Medicare beneficiaries. Chest2012;142:973-81. [PMID: 22406959] CrossrefMedlineGoogle Scholar
    • 4. Welte TTorres ANathwani DClinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax2012;67:71-9. [PMID: 20729232] doi:10.1136/thx.2009.129502 CrossrefMedlineGoogle Scholar
    • 5. van der Poll TOpal SMPathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet2009;374:1543-56. [PMID: 19880020] doi:10.1016/S0140-6736(09)61114-4 CrossrefMedlineGoogle Scholar
    • 6. Rittirsch DFlierl MAWard PAHarmful molecular mechanisms in sepsis. Nat Rev Immunol2008;8:776-87. [PMID: 18802444] doi:10.1038/nri2402 CrossrefMedlineGoogle Scholar
    • 7. Ferguson NDCook DJGuyatt GHMehta SHand LAustin Pet alOSCILLATE Trial InvestigatorsHigh-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med2013;368:795-805. [PMID: 23339639] doi:10.1056/NEJMoa1215554 CrossrefMedlineGoogle Scholar
    • 8. Erickson SEMartin GSDavis JLMatthay MAEisner MDNIH NHLBI ARDS NetworkRecent trends in acute lung injury mortality: 1996–2005. Crit Care Med2009;37:1574-9. [PMID: 19325464] doi:10.1097/CCM.0b013e31819fefdf CrossrefMedlineGoogle Scholar
    • 9. Piantadosi CASchwartz DAThe acute respiratory distress syndrome. Ann Intern Med2004;141:460-70. [PMID: 15381520] doi:10.7326/0003-4819-141-6-200409210-00012 LinkGoogle Scholar
    • 10. Montón CEwig STorres AEl-Ebiary MFilella XRañó Aet alRole of glucocorticoids on inflammatory response in nonimmunosuppressed patients with pneumonia: a pilot study. Eur Respir J1999;14:218-20. [PMID: 10489855] CrossrefMedlineGoogle Scholar
    • 11. Remmelts HHMeijvis SCBiesma DHvan Velzen-Blad HVoorn GPGrutters JCet alDexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol2012;19:1532-8. [PMID: 22855392] doi:10.1128/CVI.00423-12 CrossrefMedlineGoogle Scholar
    • 12. Nie WZhang YCheng JXiu QCorticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One2012;7:e47926. [PMID: 23112872] doi:10.1371/journal.pone.0047926 CrossrefMedlineGoogle Scholar
    • 13. Chen YLi KPu HWu TCorticosteroids for pneumonia. Cochrane Database Syst Rev2011:CD007720. [PMID: 21412908] doi:10.1002/14651858.CD007720.pub2 CrossrefMedlineGoogle Scholar
    • 14. Mandell LAWunderink RGAnzueto ABartlett JGCampbell GDDean NCet alInfectious Diseases Society of AmericaInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis2007;44 Suppl 2:S27-72. [PMID: 17278083] CrossrefMedlineGoogle Scholar
    • 15. Woodhead MBlasi FEwig SGarau JHuchon GIeven Met alJoint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious DiseasesGuidelines for the management of adult lower respiratory tract infections—full version. Clin Microbiol Infect2011;17 Suppl 6:E1-59. [PMID: 21951385] doi:10.1111/j.1469-0691.2011.03672.x CrossrefMedlineGoogle Scholar
    • 16. Blum CANigro NBriel MSchuetz PUllmer ESuter-Widmer Iet alAdjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet2015;385:1511-8. [PMID: 25608756] doi:10.1016/S0140-6736(14)62447-M151220 CrossrefMedlineGoogle Scholar
    • 17. Torres ASibila OFerrer MPolverino EMenendez RMensa Jet alEffect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA2015;313:677-86. [PMID: 25688779] doi:10.1001/jama.2015.88 CrossrefMedlineGoogle Scholar
    • 18. Guyatt GHOxman ADVist GEKunz RFalck-Ytter YAlonso-Coello Pet alGRADE Working GroupGRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6. [PMID: 18436948] doi:10.1136/bmj.39489.470347.AD CrossrefMedlineGoogle Scholar
    • 19. Busse JW, Guyatt G. Modification of Cochrane tool to assess risk of bias in randomized trials. 2013. Accessed at https://distillercer.com/wp-content/uploads/2014/02/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.docx on 24 June 2015. Google Scholar
    • 20. Akl EAJohnston BCAlonso-Coello PNeumann IEbrahim SBriel Met alAddressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One2013;8:e57132. [PMID: 23451162] doi:10.1371/journal.pone.0057132 CrossrefMedlineGoogle Scholar
    • 21. Ebrahim SJohnston BCAkl EAMustafa RASun XWalter SDet alAddressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol2014;67:560-70. [PMID: 24613497] doi:10.1016/j.jclinepi.2013.11.014 CrossrefMedlineGoogle Scholar
    • 22. Guyatt GHOxman ADKunz RBrozek JAlonso-Coello PRind Det alGRADE guidelines 6.Rating the quality of evidence—imprecision. J Clin Epidemiol2011;64:1283-93. [PMID: 21839614] doi:10.1016/j.jclinepi.2011.01.012 CrossrefMedlineGoogle Scholar
    • 23. Wan XWang WLiu JTong TEstimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol2014;14:135. [PMID: 25524443] doi:10.1186/1471-2288-14-135 CrossrefMedlineGoogle Scholar
    • 24. Confalonieri MUrbino RPotena APiattella MParigi PPuccio Get alHydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med2005;171:242-8. [PMID: 15557131] CrossrefMedlineGoogle Scholar
    • 25. Fine MJAuble TEYealy DMHanusa BHWeissfeld LASinger DEet alA prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med1997;336:243-50. [PMID: 8995086] CrossrefMedlineGoogle Scholar
    • 26. Lim WSvan der Eerden MMLaing RBoersma WGKaralus NTown GIet alDefining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax2003;58:377-82. [PMID: 12728155] CrossrefMedlineGoogle Scholar
    • 27. British Thoracic Society Standards of Care CommitteeBTS guidelines for the management of community acquired pneumonia in adults. Thorax2001;56 Suppl 4:IV1-64. [PMID: 11713364] MedlineGoogle Scholar
    • 28. Niederman MSMandell LAAnzueto ABass JBBroughton WACampbell GDet alAmerican Thoracic SocietyGuidelines for the management of adults with community-acquired pneumonia.Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med2001;163:1730-54. [PMID: 11401897] CrossrefMedlineGoogle Scholar
    • 29. Niederman MSBass JBCampbell GDFein AMGrossman RFMandell LAet alGuidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy.American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis1993;148:1418-26. [PMID: 8239186] CrossrefMedlineGoogle Scholar
    • 30. Higgins JPTAltman DGAssessing risk of bias in included studies.. In: Higgins JPT, Green S, eds., eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Chichester, United Kingdom: J Wiley; 2009. Google Scholar
    • 31. IntHout JIoannidis JPBorm GFThe Hartung–Knapp–Sidik–Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian–Laird method. BMC Med Res Methodol2014;14:25. [PMID: 24548571] doi:10.1186/1471-2288-14-25 CrossrefMedlineGoogle Scholar
    • 32. Knapp GHartung JCombined test procedures in the meta-analysis of controlled clinical trials. Stud Health Technol Inform2000;77:34-8. [PMID: 11187570] MedlineGoogle Scholar
    • 33. Guyatt GHThorlund KOxman ADWalter SDPatrick DFurukawa TAet alGRADE guidelines: 13.Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol2013;66:173-83. [PMID: 23116689] doi:10.1016/j.jclinepi.2012.08.001 CrossrefMedlineGoogle Scholar
    • 34. Yu HRubin JDunning SLi SSato RClinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc2012;60:2137-43. [PMID: 23110409] doi:10.1111/j.1532-5415.2012.04208.x CrossrefMedlineGoogle Scholar
    • 35. Charles PGWolfe RWhitby MFine MJFuller AJStirling Ret alAustralian Community-Acquired Pneumonia Study CollaborationSMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis2008;47:375-84. [PMID: 18558884] doi:10.1086/589754 CrossrefMedlineGoogle Scholar
    • 36. Toba AYamazaki MMochizuki HNoguchi TTsuda YKawate Eet alLower incidence of acute respiratory distress syndrome in community-acquired pneumonia patients aged 85 years or older. Respirology2010;15:319-25. [PMID: 20070586] doi:10.1111/j.1440-1843.2009.01685.x CrossrefMedlineGoogle Scholar
    • 37. Capelastegui AEspañaYandiola PPQuintana JMBilbao ADiez RPascual Set alPredictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest2009;136:1079-85. [PMID: 19395580] doi:10.1378/chest.08-2950 CrossrefMedlineGoogle Scholar
    • 38. Tikkinen KAAgarwal ACraigie SCartwright RGould MKHaukka Jet alSystematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev2014;3:150. [PMID: 25540016] doi:10.1186/2046-4053-3-150 CrossrefMedlineGoogle Scholar
    • 39. Wagner HNBennett ILLasagna LCluff LERosenthal MBMirick GSThe effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp1956;98:197-215. [PMID: 13304518] MedlineGoogle Scholar
    • 40. El-Ghamrawy AHShokeir MHEsmat AAEffects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egyptian Journal of Chest2006;55:91-9. Google Scholar
    • 41. Nafae RMRagab MIAmany FMRashed SBAdjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis2013;62:439-45. CrossrefGoogle Scholar
    • 42. Snijders DDaniels JMde Graaff CSvan der Werf TSBoersma WGEfficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med2010;181:975-82. [PMID: 20133929] doi:10.1164/rccm.200905-0808OC CrossrefMedlineGoogle Scholar
    • 43. Meijvis SCHardeman HRemmelts HHHeijligenberg RRijkers GTvan Velzen-Blad Het alDexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet2011;377:2023-30. [PMID: 21636122] doi:10.1016/S0140-6736(11)60607-7 CrossrefMedlineGoogle Scholar
    • 44. Mikami KSuzuki MKitagawa HKawakami MHirota NYamaguchi Het alEfficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung2007;185:249-55. [PMID: 17710485] CrossrefMedlineGoogle Scholar
    • 45. McHardy VUSchonell MEAmpicillin dosage and use of prednisolone in treatment of pneumonia: co-operative controlled trial. Br Med J1972;4:569-73. [PMID: 4404939] CrossrefMedlineGoogle Scholar
    • 46. Fernández-Serrano SDorca JGarcia-Vidal CFernández-Sabé NCarratalà JFernández-Agüera Aet alEffect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care2011;15:R96. [PMID: 21406101] doi:10.1186/cc10103 CrossrefMedlineGoogle Scholar
    • 47. Sabry NAOmar EECorticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm2011;2:73-81. CrossrefGoogle Scholar
    • 48. Marik PKraus PSribante JHavlik ILipman JJohnson DWHydrocortisone and tumor necrosis factor in severe community-acquired pneumonia.A randomized controlled study. Chest1993;104:389-92. [PMID: 8339624] CrossrefMedlineGoogle Scholar
    • 49. Bernard GRArtigas ABrigham KLCarlet JFalke KHudson Let alThe American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med1994;149:818-24. [PMID: 7509706] CrossrefMedlineGoogle Scholar
    • 50. Montori VMDevereaux PJAdhikari NKBurns KEEggert CHBriel Met alRandomized trials stopped early for benefit: a systematic review. JAMA2005;294:2203-9. [PMID: 16264162] CrossrefMedlineGoogle Scholar
    • 51. Bassler DBriel MMontori VMLane MGlasziou PZhou Qet alSTOPIT-2 Study GroupStopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA2010;303:1180-7. [PMID: 20332404] doi:10.1001/jama.2010.310 CrossrefMedlineGoogle Scholar
    • 52. Oxman ADGuyatt GHA consumer's guide to subgroup analyses. Ann Intern Med1992;116:78-84. [PMID: 1530753] doi:10.7326/0003-4819-116-1-78 LinkGoogle Scholar
    • 53. Sun XBriel MWalter SDGuyatt GHIs a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ2010;340:c117. [PMID: 20354011] doi:10.1136/bmj.c117 CrossrefMedlineGoogle Scholar
    • 54. Cheng MPan ZYYang JGao YDCorticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care2014;59:557-63. [PMID: 24046464] doi:10.4187/respcare.02758 CrossrefMedlineGoogle Scholar
    • 55. Walters JATan DJWhite CJGibson PGWood-Baker RWalters EHSystemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev2014;9:CD001288. [PMID: 25178099] doi:10.1002/14651858.CD001288.pub4 CrossrefMedlineGoogle Scholar
    • 56. Peter JVJohn PGraham PLMoran JLGeorge IABersten ACorticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ2008;336:1006-9. [PMID: 18434379] doi:10.1136/bmj.39537.939039.BE CrossrefMedlineGoogle Scholar
    • 57. Bone RCFisher CJClemmer TPSlotman GJMetz CAEarly methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest1987;92:1032-6. [PMID: 3315478] CrossrefMedlineGoogle Scholar